Impact of clopidogrel on postoperative blood loss after non-elective coronary bypass surgery

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Transfusion Medicine

Background:

• Coronary artery bypass grafting (CABG) is a common cardiac procedure.
• Antiplatelet medications like clopidogrel and aspirin (ASA) are frequently used perioperatively.
• The impact of clopidogrel on outcomes following CABG requires further clarification.

Purpose of the Study:

• To investigate the effects of clopidogrel on blood loss and transfusion requirements after CABG.
• To assess the association between clopidogrel exposure and reoperation for bleeding.
• To evaluate the influence of clopidogrel on early postoperative outcomes.

Main Methods:

• Retrospective analysis of 182 patients undergoing urgent or emergent CABG.
• Patients were categorized into four groups: clopidogrel exposure, ASA and clopidogrel exposure, ASA exposure, and no antiplatelet therapy.
• Outcomes assessed included chest tube drainage, reoperation for bleeding, blood product usage, duration of mechanical ventilation, and ICU/hospital stay.

Main Results:

• Clopidogrel exposure was associated with significantly higher total chest tube drainage in the first 24 hours.
• Patients with clopidogrel exposure required more blood product transfusions and significantly more reoperations for bleeding.
• Longer durations of mechanical ventilation and intensive care unit stay were observed in the clopidogrel group.

Conclusions:

• Recent clopidogrel treatment is linked to increased blood loss, transfusion requirements, and reoperation rates after CABG.
• Clopidogrel use may negatively impact early postoperative recovery, necessitating careful consideration in CABG patients.
• Further research is warranted to optimize antiplatelet strategies in patients undergoing CABG.